TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03291743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy
Description: PillCam(TM) CROHN'S CAPSULE
Study: NCT02430467

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver-guided pain management training (CG-PMT)
Description: Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment-as-usual (TAU)
Description: Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
Study: NCT01346319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-SLV361
Description: For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
Study: NCT02809547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dried Blood Spot device
Study: NCT03333798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention
Description: A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~* The Cognitive-Behavioral model~* Tackling traumatic events~* Cognitive reprocessing~* Relaxation techniques~* Prevention of revictimization~* Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychosocial care
Description: The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used.
Study: NCT00259064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04077619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modern pain neuroscience approach
Description: Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care physiotherapy
Description: Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
Study: NCT03233529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2% BID
Description: Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment (vehicle)
Description: Placebo ointment (vehicle) BID for 15 days (double blind)
Study: NCT01075256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% calcium sodium phosphosilicate toothpaste
Description: Low concentration calcium sodium phosphosilicate tubule occlusion agent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 7.5% calcium sodium phosphosilicate toothpaste
Description: High concentration calcium sodium phosphosilicate tubule occlusion agent
Study: NCT03120156

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No insoles
Description: control group with no insoles in the shoes
Study: NCT03042455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo and rTMS
Description: The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo
Description: The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
Study: NCT03793725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: Anti-PD-1 Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Anti-angiogenic drugs
Study: NCT02127996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline
Study: NCT06404593

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.
Study: NCT01075256

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: Placebo toothpaste
Study: NCT00800592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: 10 mg sildenafil bolus
Study: NCT03833635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: the sham intervention consists in a stable skin-to-skin contact with the participant
Study: NCT00639730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: High fat, low carbohydrate diet
Study: NCT03717090

Intervention type: OTHER
Intervention: No intervention
Description: Sample collection study Sample collection and collection of laboratory values
Study: NCT01202942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quest
Description: Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
Study: NCT01180543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oplon Active Patch
Description: Patches are placed over acne lesion overnight. Treatment is a single treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: same as active patch
Study: NCT00615264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
Study: NCT00969397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antiangiogenic
Description: Topical Antiangiogenic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser
Description: Pulsed Dye Laser
Study: NCT00058422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study: NCT01839422

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory assessment
Description: Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory assessment
Description: Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory assessment
Description: Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI
Description: Brain imaging examination : Structural and functional MRI to compare differences between each sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI
Description: Brain imaging examination : Structural and functional MRI to compare differences between each sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI
Description: Brain imaging examination : Structural and functional MRI to compare differences between each sample.
Study: NCT00048672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: Starting dose of 400 mg orally daily.
Study: NCT03462394

Intervention type: OTHER
Intervention: Current Script
Description: This is the version of the phone call script currently used at NYU Langone Health.

Intervention type: OTHER
Intervention: Alternate Script Iterations
Description: Intervention includes various iterations of the phone call script (different wording or script structure).
Study: NCT02287584

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DSP-5423P Placebo
Description: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P 40mg
Description: DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P 80mg
Description: DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P Placebo-to-Flex
Description: DSP-5423P Placebo:~DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P Active-to-Flex
Description: DSP-5423P Active:~DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily~DSP-5423P Flex:~DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily
Study: NCT06261983

Intervention type: PROCEDURE
Intervention: Sentinel node biopsy guided by magnetic probe
Description: Sentinel nodes exeresis guided by magnetic probe after injection submucosally and peritumorally of super-para-magnetic contrast. Standard neck dissection (levels I-II) were carry out after sentinel node biopsy
Study: NCT01062113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Study: NCT01605435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin Group 1
Description: The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
Study: NCT01062113

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
Study: NCT00637130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.0008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.001%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.0012%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAVATAN

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT02438943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audit
Description: An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
Study: NCT01605435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin Group 2
Description: The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
Study: NCT02649244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Family Caregiver Training Program
Description: The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
Study: NCT02708537

Intervention type: BIOLOGICAL
Intervention: PRGF in candidates for sperm donors
Description: PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
Study: NCT02614742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SFX-01
Description: An intervention releasing sulforaphane.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo otherwise identical to Active product
Study: NCT02731651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open hysterectomy
Description: Hysterectomy with laparotomy incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic assisted vaginal hysterectomy
Description: Hysterectomy with laparoscopic assisstance.
Study: NCT00625417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histopathologic examination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: light-scattering spectroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT01762202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Study: NCT03137940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
Study: NCT00976976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, capecitabine, cisplatin
Description: Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
Study: NCT06404593

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.
Study: NCT02184273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium metamizol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03919201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance band exercise intervention
Description: Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No exercise intervention group
Description: Control group: no exercise intervention
Study: NCT02520115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Analysis of serum and tissue samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Analysis of serum and tissue samples
Study: NCT03871205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen loaded DC vaccine
Description: Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
Study: NCT03247153

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Imaging of the heart using ultrasound
Study: NCT02041117

Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
Study: NCT01131143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Voice
Description: A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic Voice
Description: A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.